Primary Sclerosing Cholangitis clinical trials at University of California Health

5 in progress, 3 open to eligible people

Showing trials for

  • A Study of Experimental PLN-74809 in Cholangitis and Suspected Liver Fibrosis

    open to eligible people ages 18-75

    A Phase 2a, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, study to evaluate the safety, tolerability, and PK of PLN-74809 in participants with primary sclerosing cholangitis and suspected liver fibrosis

    at UC Davis UCSF

  • A Study of Volixibat to Treat Itching Caused by Primary Sclerosing Cholangitis

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    open to eligible people ages 18 years and up

    The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.

    at UC Davis

  • Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

    open to eligible people ages 15-80

    This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers of liver injury in PSC; 2) improves PSC patient symptoms; and 3) is safe in patients with PSC.

    at UC Davis

  • Cholangioscopy in Primary Sclerosing Cholangitis (PSC)

    Sorry, in progress, not accepting new patients

    To demonstrate the clinical utility of the addition of per oral cholangioscopy (POCS) to standard endoscopic retrograde cholangiopancreatography (ERCP) with brushing cytology for diagnosis and early detection of cholangiocarcinoma in patients diagnosed with primary sclerosing cholangitis (PSC).

    at UC Davis

  • Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis

    Sorry, in progress, not accepting new patients

    The primary objective of this study is to evaluate whether cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).

    at UC Davis UCSD UCSF

Our lead scientists for Primary Sclerosing Cholangitis research studies include .

Last updated: